DICE Therapeutics (NASDAQ:DICE) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group started coverage on shares of DICE Therapeutics (NASDAQ:DICE – Get Rating) in a research note published on Monday, Briefing.com reports. The brokerage issued a buy rating and a $71.00 price target on the stock.

Other analysts also recently issued reports about the company. Needham & Company LLC started coverage on DICE Therapeutics in a research report on Friday, March 31st. They set a buy rating and a $56.00 target price for the company. TD Cowen initiated coverage on DICE Therapeutics in a report on Wednesday, March 1st. They issued an outperform rating for the company. Cowen assumed coverage on DICE Therapeutics in a research note on Wednesday, March 1st. They issued an outperform rating on the stock. Cowen assumed coverage on DICE Therapeutics in a research note on Wednesday, March 1st. They set an outperform rating on the stock. Finally, HC Wainwright reaffirmed a buy rating and set a $60.00 target price on shares of DICE Therapeutics in a report on Thursday, March 16th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $62.60.

DICE Therapeutics Stock Down 2.0 %

Shares of NASDAQ:DICE opened at $33.15 on Monday. The firm’s 50 day moving average price is $31.34 and its 200-day moving average price is $31.26. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $45.99. The stock has a market capitalization of $1.58 billion, a PE ratio of -15.21 and a beta of 0.69.

DICE Therapeutics (NASDAQ:DICE – Get Rating) last announced its quarterly earnings data on Wednesday, March 15th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). Analysts expect that DICE Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Richard H. Scheller sold 84,097 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $38.51, for a total transaction of $3,238,575.47. Following the transaction, the director now owns 8,427 shares in the company, valued at approximately $324,523.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Richard H. Scheller sold 84,097 shares of the business’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $38.51, for a total value of $3,238,575.47. Following the transaction, the director now owns 8,427 shares of the company’s stock, valued at $324,523.77. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Scott M. Robertson sold 18,750 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $36.55, for a total value of $685,312.50. Following the completion of the transaction, the chief financial officer now directly owns 198,000 shares in the company, valued at approximately $7,236,900. The disclosure for this sale can be found here. In the last quarter, insiders have bought 372,590 shares of company stock worth $10,239,252 and have sold 154,210 shares worth $5,611,071. 4.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its position in DICE Therapeutics by 18.4% during the first quarter. JPMorgan Chase & Co. now owns 10,089 shares of the company’s stock worth $193,000 after purchasing an additional 1,567 shares in the last quarter. Bank of New York Mellon Corp boosted its position in DICE Therapeutics by 15.6% during the first quarter. Bank of New York Mellon Corp now owns 38,535 shares of the company’s stock worth $737,000 after purchasing an additional 5,192 shares in the last quarter. MetLife Investment Management LLC boosted its position in DICE Therapeutics by 55.4% during the first quarter. MetLife Investment Management LLC now owns 9,471 shares of the company’s stock worth $181,000 after purchasing an additional 3,377 shares in the last quarter. Rhumbline Advisers lifted its position in shares of DICE Therapeutics by 41.2% in the first quarter. Rhumbline Advisers now owns 14,590 shares of the company’s stock valued at $279,000 after acquiring an additional 4,258 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of DICE Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 860,540 shares of the company’s stock valued at $16,462,000 after acquiring an additional 5,245 shares in the last quarter. Institutional investors and hedge funds own 91.51% of the company’s stock.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.